Preclinical and first-in-human phase I clinical evaluation of Stampidine, a potent anti-HIV Pharmaceutical drug candidate

Journal of AIDS and Clinical Research

Volumn 3, Issue 1, 2012, Pages

  Cahn, Pedro ^a,b,c   Rolon, Maria Jose ^b   Gun, Ana Mirta ^b   Ferrari, Ines ^d,e   Dibirdik, Ilker ^f,g   Qazi, Sanjive ^f,g   D'Cruz, Osmond ^f,g,i   Sahin, Kazim ^h   Uckun, Fatih ^g,i,j  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d Laboratorio de Bioequivalencia y Biologia Molecular   (France)

^e Ciudad Autonoma de Buenos Aires ^*  (Argentina)

^f Paradigm Pharmaceuticals   (United States)

^g PARKER HUGHES INSTITUTE   (United States)

^h FIRAT UNIVERSITY   (Turkey)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858244055     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000138     Document Type: Article

References (34)

1. The AIDS Institute Global Fact Sheet
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323:1304-1307.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
4. Smit C, Geskus R, Uitenbroek D, Mulder D, Van Den Hoek A, et al. (2004) Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology 15: 536-542.
5. Shafer R, Kantor R, Gonzales MJ (2000) The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2: 211-228.
6. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, et al. (2005) HIV protease and reverse transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug resistance surveillance. J Infect Dis 192: 456-465.
7. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et al. (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2: e112.
8. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, et al. (2010) Update of the Drug Resistance Mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
9. CDC (2011) Pre-exposure prophyxaxis (PrEP).
10. AIDS Vaccine Advocacy Coalition. Global advocacy for HIV prevention. Ongoing PrEP trials.
11. Mayer KH, Venkatesh KK (2010) Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 55 Suppl 2: S122-127.
12. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR (2011) Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 204: 488. e1-8.
13. Kelesidis T, Landovitz RJ (2011) Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 8: 94-103.
14. Hurt CB, Eron JJ Jr, Cohen MS (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 53: 1265-1270.
15. Das K, Bandwar RP, White KL, Feng JY, Sarafianos SG, et al. (2009) Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 284: 35092-35100.
16. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, et al. (2004) Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 48: 992-1003.
17. Hurt CB, Eron JJ Jr, Cohen MS (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 53: 1265-1270.
18. FHI 360: VOICE September 2011 Update: VOICE HIV prevention trial continues, but researchers suspend oral tenofovir arm because of futility (September 28, 2011).
19. FHI 360: FEM-PrEP June 2011 Update: FEM-PrEP study will be highly unlikely to demonstrate Truvada's effectiveness in preventing HIV infection in the study population.
20. Uckun FM (2006) Unmet challenges in HIV therapy and potential of stampidine. Arzneimittelforschung 56: 117-120.
21. Uckun FM (2006) Aryl phosphate derivatives of d4T having activity against resistant HIV strains. US Patent No. 7144874. Issue Date: December 5, 2006.
22. Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, et al. (2007) Intracellular nucleoside trophosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 12: 981-986.
23. Venkatachalam TK, Tai HL, Vig R, Chen CL, Jan ST, Uckun FM (1998) Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg Med Chem Lett 8: 3121-3126.
24. Uckun FM, Qazi S, Venkatachalam TK (2005). In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 55: 223-231.
25. Uckun FM, Chen CL, Lisowski E, Mitcheltree GC, Venkatachalam TK, et al. (2003) Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforschung 53: 357-367.
26. Chen CL, Venkatachalam TK, Zhu ZH, Uckun FM (2001) In vivo pharmacokinetics and metabolism of anti-HIV agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] in mice. Drug Metab Dispos 29: 1035-1041.
27. Chen CL, Yu G, Venkatachalam T, Uckun FM (2002) Metabolism of stavudine-5'-[p-bromophenyl methoxy alaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 30: 1523-1531.
28. Johnston E, Dupnik KM, Gonzales MJ, Winters MA, Rhee SY, et al. (2005) Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 19: 731-733.
29. Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, et al. (2002) In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 46: 3428-3436.
30. Uckun FM, Chen CL, Samuel P, Pendergrass S, Uckun FM (2003) In vivo antiretroviral activity of stampidine in chronically FIV-infected cats. Antimicrob Agents Chemother 47: 1233-1240.
31. DuMez D, Venkatachalam TK, Uckun FM (2006) Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittelforschung 56: 136-151.
32. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D (2002) Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 46: 3613-3616.
33. Uckun FM, DuMez D, Qazi S, Tibbles H, Venkatachalam TK (2007) Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 57: 112-121.
34. Uckun FM, Waurzyniak B, Tibbles H, Venkatachalam TK, Erbeck D (2006) In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 56: 176-192.